MIRA PHARMACEUTICALS, INC. Logo

MIRA PHARMACEUTICALS, INC.

Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.

MIRA | NDAQ

Overview

Corporate Details

ISIN(s):
US60458C1045
LEI:
Country:
United States of America
Address:
1200 BRICKELL AVENUE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic and neuropsychiatric disorders. The company's pipeline is centered on two primary neuroscience programs. One program is developing Ketamir-2, a next-generation oral ketamine analog. The other is focused on a new molecular synthetic analog of THC (tetrahydrocannabinol). MIRA aims to address unmet medical needs by creating advanced, patent-protected treatment options for a range of central nervous system conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MIRA PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MIRA PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MIRA PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America DRUG
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea 003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America BNR
C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America CLDI

Talk to a Data Expert

Have a question? We'll get back to you promptly.